Skip to main content
Mark Gruenhaupt headshot

Mark F. Gruenhaupt

RPh
Senior Pharmacy Management Consultant
Chicago, IL, US
Main +1 262 784 2250 | Office +1 262 923 3699

Mark Gruenhaupt is a senior pharmacy management consultant with the Chicago office of Milliman. He joined the firm in 2022.

Download bioDownload

Experience

Mark has over 30 years of experience in the pharmacy and managed care industry. Mark’s areas of expertise include rebate and formulary strategy, clinical and plan performance analytics, pharmacy network pricing, pharmaceutical pipeline impacts, and Medicare Part D requirements and regulations. Mark has extensive experience with account and client relationship management, having worked with regional and national health plans and PBMs in both the commercial and government sectors. He leads client engagement and supports strategic projects to help payers with pharmacy benefit design and supply chain strategies that improve health and lower costs.

Prior to joining Milliman, Mark worked as director of rebate and clinical strategy for a pharmacy benefit manager, where he managed all aspects of client relations and financial operations of the pharmacy programs.

Publications

Read their latest work

Article

Direct-to-patient prescription drugs: A framework to help pharmaceutical manufacturers evaluate their strategy

19 March 2026 - by Michelle (Klein) Robb, Mark F. Gruenhaupt, Jake K. Klaisner
We outline considerations on evaluating medication suitability for manufacturers looking to expand their presence in the direct-to-patient market.
Article

The evolving landscape of anti-obesity medication coverage in Medicaid

19 March 2026 - by Amine Elmeghni, Mark F. Gruenhaupt, Kristin Niakan
We expect states to continue balancing the coverage of anti-obesity drugs with immediate budget risks, as cuts to federal Medicaid take effect.
Article

6 things for healthcare stakeholders to know about GLP-1s and compounding

16 July 2025 - by Mark F. Gruenhaupt, Peter Heinen
We review key points for healthcare stakeholders to consider as compounding pharmacies produce GLP-1 medications.
Article

Prescribing a Part D formulary for the new IRA world

13 December 2024 - by Madeleine Feller, Justin Harris, Jian-ya Lin, Mark F. Gruenhaupt
Medicare Part D: We highlight the changes in plan incentives and key trends in 2025 formulary coverage, along with considerations for 2026.
Video

Evolution in PBM market dynamics: How change impacts pharmacy supply chain

30 October 2024 - by Mark F. Gruenhaupt, Matthew Hayes, Kristin Niakan
Hear how pharmacy benefit manager profits are shifting amid new rebate credits, legislative trends, and PBMs’ expansion into biosimilars distribution.
Article

Payer strategies for GLP-1 medications for weight loss

25 August 2023 - by AJ Ally, Deana Bell, Melody Craff, Jeff Garbe, Mark F. Gruenhaupt, Peter Heinen, Ellyn Russo
We examine various strategies related to GLP-1 medications such as Wegovy when used for weight loss to help payers understand the landscape, develop a coverage strategy, and minimize waste.